AIM:To study the chemical constituents of Lysimachia clethroide Duby. METHODS:Chromatographic techniques,including MS and NMR,were used to isolate and purify the constituents based on column chromatography separation on silica gel,Sephadex LH-20 and Semipreparative RP-HPLC. RESULTS:Eleven flavonoids were obtained and elucidated as: kaempferol (1),kaempferol 3-O-?-D-glucopyranoside (2),kaempferol 3-O-?-D-galactoside (3),kaempferol 3-O-?-D-(6″-p-coumaroyl)-glucopyranoside (4),quercetin (5),Isorhamnetin (6) ,quercetin 3-O-?-D-galactoside (7),quercetin 3′-methoxy-3-O-?-D-galactoside (8),quercetin 3-O-?-D-(6″-p-coumaroyl)-galactoside (9),4′-methoxy-5,6-dihydroxyisoflavone-7-O-?-D-glucopyranoside (10),7-O-glucosyl liquiritigenin (11). CONCLUSION: Compounds 3,6 were isolated from this plant and compounds 8-11 were isolated from this genus for the first time.

Objective The purpose of this study was to investigate the chemical constituents of Pierre. Methods The chemical compositions were isolated by silica gel column chromatography, semi-preparative HPLC,Sephadex LH-20, and MPLC packed with MCI gel, and their structures were identified on the basis of chemical and spectroscopic evidence (NMR and MS) . Results Eight compounds were obtained and determined as fibraurin (1),makisterone A (2),cycloartenol (3),feruloylphenethylamine (4),trans- -feruloyltyramine(5),β-sitosterol(6),1-monopalmitin(7),1-sinapoyl-β-D-glucopyranoside(8). Conclusion Compounds 2-8 were isolated from this plant for the first time.

Objective: To analyze the clinical and pathological features and prognostic factors of neuroendocrine carcinoma of the cervix (NECC). Methods: The clinical data of 35 cases of NECC treated in Shanxi Provincial Cancer Hospital from January 2006 to May 2014 were retrospectively analyzed. Results: The median age of 35 cases of NECC was 43 years old. The infection rate of human papillomavirus (HPV) 18 type was 66.7% (10/15) in 15 NECC patients who were tested with HPV. The accuracy rate of diagnosis was 14.3% (5/35) before procedure. The positive detection rate of Syn, CgA, AE1/AE3, P63 and NSE were respectively 100.0% (35/35), 80.0% (28/35), 100.0% (35/35), 34.3% (12/35) and 57.1% (20/35). The 3-year overall survival rate of 35 NECC cases was 34.29% (12/35). The age, volume of local tumor and degrees of interstitial infiltration were the main prognostic factors of patients with NECC(all P < 0.05). Conclusions NECC is easily misdiagnosed by pathomorphological examination alone, the accuracy of diagnosis could be improved by detecting neuroendocrine carcinoma markers with immunohistochemical method. The infection rate of HPV18 is higher than the others in NECC. The volume of local tumor is one of the main prognostic factors for NECC patients.

Adult ; Asian Continental Ancestry Group ; Case-Control Studies ; Female ; Glypicans ; blood ; Humans ; Male ; Metabolic Syndrome ; blood ; Middle Aged

BACKGROUND: LY01005 (Goserelin acetate sustained-release microsphere injection) is a modified gonadotropin-releasing hormone (GnRH) agonist injected monthly. This phase III trial study aimed to evaluated the efficacy and safety of LY01005 in Chinese patients with prostate cancer. METHODS: We conducted a randomized controlled, open-label, non-inferiority trial across 49 sites in China. This study included 290 patients with prostate cancer who received either LY01005 or goserelin implants every 28 days for three injections. The primary efficacy endpoints were the percentage of patients with testosterone suppression ≤50 ng/dL at day 29 and the cumulative probability of testosterone ≤50 ng/dL from day 29 to 85. Non-inferiority was prespecified at a margin of -10%. Secondary endpoints included significant castration (≤20 ng/dL), testosterone surge within 72 h following repeated dosing, and changes in luteinizing hormone, follicle-stimulating hormone, and prostate specific antigen levels. RESULTS: On day 29, in the LY01005 and goserelin implant groups, testosterone concentrations fell below medical-castration levels in 99.3% (142/143) and 100% (140/140) of patients, respectively, with a difference of -0.7% (95% confidence interval [CI], -3.9% to 2.0%) between the two groups. The cumulative probabilities of maintaining castration from days 29 to 85 were 99.3% and 97.8%, respectively, with a between-group difference of 1.5% (95% CI, -1.3% to 4.4%). Both results met the criterion for non-inferiority. Secondary endpoints were similar between groups. Both treatments were well-tolerated. LY01005 was associated with fewer injection-site reactions than the goserelin implant (0% vs . 1.4% [2/145]). CONCLUSION: LY01005 is as effective as goserelin implants in reducing testosterone to castration levels, with a similar safety profile. TRIAL REGISTRATION ClinicalTrials.gov, NCT04563936.
Humans ; Male ; Antineoplastic Agents, Hormonal/therapeutic use* ; East Asian People ; Gonadotropin-Releasing Hormone/agonists* ; Goserelin/therapeutic use* ; Prostate-Specific Antigen ; Prostatic Neoplasms/drug therapy* ; Testosterone